Drug Targeting Organ-Specific Strategies

380 Index
lipoproteins 6, 32, 94, 102
liposomes 3, 101, 220
– clinical applications 11, 12, 114, 225
– immunoliposomes 3, 47, 48, 181, 221
– in brain targeting 47
– in liver targeting 101
– in lung targeting 81
– in tumor targeting 220
– pharmacokinetic modelling 364
– stealth 220
liver 89, 309
– animal models, see animal models
(of disease)
– cells of the 90, 107
– drug targeting to 99, 106, 108, 114,
365
– infectious diseases 114
– inflammation 89, 93, 94, 96
– fibrosis 89, 95, 96, 321
– (human) liver slices 311
low molecular weight proteins, see proteins,
modified (plasma)
lung
– aerosol generation 63
– air flow resistance 74
– cells of the 59, 60
– drug targeting to 81
– particle deposition 57
– pulmonary delivery for systemic absorption
54, 58, 60, 82
– inspiratory flow measurement 77
– inspiratory pressure 75
– in vitro deposition 78, 80
– in vitro models for epithelial transport
62
– in vitro particle size analysis 78
– in vivo deposition 80
– tissue slices 327
– morphology, function 55
lymphoma 200, 222
lysosomes, see also drug release 8, 108
lysozyme, see also low molecular weight
proteins
– in renal targeting 137
m
mammalian expression systems 295
mannose receptors 92, 94
micelles, polymeric 7
microspheres 6
monoclonal antibodies, see antibodies
multi-drug resistance see tumor
n
nanoparticles 6
neoglycoproteins, see proteins, modified
(plasma)
nephritis 150
nephropathy, diabetic 150
NFκB, see inflammation
NSAIDs 103, 111, 137, 184
o
opsonization 101
organ transplant rejection 53, 175
organ perfusion 336, 361
OROS-CT 162, 166
p
parenchymal cells, see hepatocyte
Parkinson´s disease 24
PEG, modification with 2, 6, 43, 46, 47,
219, 220, 225
peptides
– as homing ligands 4, 103, 181, 246, 279,
281, 302, 322
– engineering in phage display 267
– formulations for pulmonary delivery 69
– pulmonary delivery of 54
– pulmonary delivery for systemic absorption
58, 82
– phage display 259, 282
– VIP analogues for brain targeting 43
phage display 255
– antibody libraries 212, 260
– cDNA expression libraries 262
– in vivo selection strategies 266
– libraries 255, 258
– ligands for drug targeting 263
– peptide libraries 259
– protein libraries 261
– selection strategies 258, 264, 265, 266
– target identification 264
pharmacodynamics 333, 337
pharmacokinetic considerations
– drug – carrier conjugate 334
– in drug targeting 351
– pro-drug 334
pharmacokinetic/pharmacodynamic modelling
333, 337
– data analysis 346
– effectiveness of drug targeting 357, 359,
363
– pharmacodynamic models 344
– pharmacokinetic models 338, 340
– pharmacokinetic/pharmacodynamic models
345
– for drug targeting 351, 364, 367
– for regional drug administration 365
– for controlled drug delivery 366
– for macromolecular carriers 366
– limitations 363
– modelling 343, 359
– simulations 346, 360
– software 366
pharmacokinetics 333, 335
physiologically-based models 340